Search

Displaying results 4271 - 4280 of 10000 in total
  1. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).

  2. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models

  3. Drug

    Bevantolol

    go.drugbank.com/drugs/DB01295
    Investigational

    Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.

  4. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    diphtheriae* grown in another culture. … Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  5. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

  6. Drug

    Morrhuic acid

    go.drugbank.com/drugs/DB14087
    Investigational

    Morrhuic acid is a mixture of unsaturated fatty acids obtained from cod liver oil.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.

  8. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  9. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)."

  10. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].